Yoon‐Koo Kang

机构：Ulsan College, Asan Medical Center, University of Ulsan, Robotics Research (United States), Hyundai Motors (South Korea) · ORCID：0000-0003-0783-6583

发表论文 863 篇 · 总被引 62220 次 · h-index 95

代表论文

• Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC (2025 · Journal of Hepatology · 被引 136)
• Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study (2025 · The Lancet Oncology · 被引 26)
• Final analysis of the randomized phase 2 part of the ASPEN-06 study: A phase 2/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric/gastroesophageal cancer (GC). (2025 · Journal of Clinical Oncology · 被引 16)
• EORTC-1203 GITC "INNOVATION": Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy of HER-2 positive stomach cancer: Overall survival results. (2025 · Journal of Clinical Oncology · 被引 14)
• Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer (2025 · Journal for ImmunoTherapy of Cancer · 被引 9)
• Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial (2025 · Nature Communications · 被引 8)